

Press release
Lund 22 Dec 2021

Scandinavian ChemoTech achieves clinical success within the subsidiary Vetiqure AB

After the treating veterinarian at Evidensia Specialist Animal Hospital Helsingborg carried out the last follow-up of the dog that was treated in the autumn of 2021, a very good clinical result can be confirmed.

During the late summer, the Company's subsidiary within Animal Care began a collaboration with Evidensia Specialist Animal Hospital Helsingborg, where vetIQure™ with its Tumour Specific Electroporation technology (TSE) is currently being evaluated on both small animals and horses.

"A dog with a giant cell tumour in the palate has been treated with a positive outcome. It was a very difficult-to-treat tumour that has not responded to other types of treatment. After a successful treatment with TSE, follow-up tests now show that no tumour cells remain in the area." - says treating veterinarian Majbritt Larsen at Evidensia Specialist Animal Hospital Helsingborg.

"It is fantastic to hear that the benefits of TSE also demonstrate a complete tumour response in veterinary medicine as well. The results and feedback naturally affect our opportunities for commercial success in our Animal Care business area." - says CEO Mohan Frick

For more information, please contact:
Mohan Frick, CEO

+46 (0)10-218 93 00
info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se